Interim analysis of another clinical trial involving three patients (age range 16–26 years old) with CNS tumors that received six to nine locoregional doses of HER-2-CAR-T cells demonstrated clinical evidence of feasibility and safety (NCT03500991) [49]. This evidence concerns the gene ERBB2 and central nervous system neoplasm.